2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…2019 American Transplant Congress
Implementation of Novel Machine-Learning Techniques to Tailor Donornet® Organ Offers to Center and Surgeon Preference
Transplant Center, Massachusetts General Hospital, Boston, MA
*Purpose: Real-time communication regarding organ placement is critical. For this purpose, UNOS launched DonorNet®, a computerized allocation algorithm, to aid and facilitate organ placement. However,…2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…2019 American Transplant Congress
Blood Group Incompatible Living Donor Kidney Transplantation in Patients with End-Stage Kidney Disease Due to Diabetes Kidney Disease
*Purpose: Diabetes is a growing public health problem, and diabetes kidney disease (DKD) is the most prevalent chronic kidney disease and the major cause of…2019 American Transplant Congress
Exploration of the Stanford Integrated Psychosocial Assessment for Transplant with Psychosocial and Medical Outcomes in Kidney/Kidney-Pancreas Transplant Recipients
*Purpose: The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) is a psychometric instrument designed to improve organ transplant patient selection. However, limited studies have been…2019 American Transplant Congress
A Comparison of the Safety and Efficacy of Apixaban Use in Renal Transplant vs. Non-Renal Transplant Recipients
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Background: Utilization of direct-acting oral anticoagulants has become a preferred method for chronic anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).…2019 American Transplant Congress
Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study
1Study Group, Hephaistos, Germany, 2Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was set up to compare early use of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus standard-dose tacrolimus [TAC-C) in de…2019 American Transplant Congress
Treprostinil as a Bridge Therapy to Heart-Lung Transplants with Severe Pulmonary Arterial Hypertension
*Purpose: Heart-lung transplants (HLTx) is the only one effective strategy for advanced pulmonary arterial hypertension (PAH) with refractory right heart failure. But limited availability of…2019 American Transplant Congress
Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare the antirejection efficacy outcomes of an everolimus+reduced-exposure CNI (EVR+rCNI) vs mycophenolic acid+standard-exposure CNI (MPA+sCNI) regimen in renal transplant recipients (RTxRs) from the…2019 American Transplant Congress
Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Solid Organ Transplant Recipients
Tampa General Hospital, Tampa, FL
*Purpose: The use of direct oral anticoagulants (DOACs) has not been fully adopted by the solid organ transplant (SOT) community due to factors including, fluctuating…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »